PMDA drug package insert

ヘパリンNa透析用150単位/mLシリンジ20mL「NIG」

PMDA Prescription drug · 日医工岐阜工場株式会社 · package insert Feb 1, 2026

Key facts

Brand names ヘパリンNa透析用150単位/mLシリンジ20mL「NIG」, ヘパリンNa透析用200単位/mLシリンジ20mL「NIG」, ヘパリンNa透析用250単位/mLシリンジ20mL「NIG」
Nonproprietary names ヘパリンナトリウム
Companies 製造販売元/日医工岐阜工場株式会社, 販売元/日医工株式会社
Product type Prescription drug
Therapeutic category 血液凝固阻止剤
Therapeutic category codes 873334
YJ codes 3334402G8050, 3334402P1056, 3334402P2060
Approval numbers 21800AMZ10186, 21800AMZ10188, 21800AMZ10190
Package insert edition 第4版
Package insert date Feb 1, 2026
PMDA document key 581120_3334402G8050_1
PMDA company code 581120

At a glance

  • 1–9 Package insert revisions
  • 10–99 Related PMDA documents
  • None Safety communications
  • No PMDA review report published
  • No Risk management plan (RMP)

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMDA approved drugs and package inserts (Japan)

Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.

Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date:

Browse all PMDA approved drugs and package inserts (Japan)